Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PLETHICO PHARMA vs MYLAN (US) - Comparison Results

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 PLETHICO PHARMA   MYLAN
EQUITY SHARE DATA
    PLETHICO PHARMA
Mar-14
MYLAN
Dec-18
PLETHICO PHARMA/
MYLAN
5-Yr Chart
Click to enlarge
High Rs2543,978-   
Low Rs312,190-   
Sales per share (Unadj.) Rs604.61,830.6-  
Earnings per share (Unadj.) Rs32.549.7-  
Cash flow per share (Unadj.) Rs51.3392.5-  
Dividends per share (Unadj.) Rs00-  
Avg Dividend yield %00-  
Book value per share (Unadj.) Rs473.71,980.4-  
Shares outstanding (eoy) m34.07514.50-   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x0.21.7 14.0%   
Avg P/E ratio x4.462.0 7.1%  
P/CF ratio (eoy) x2.87.9 35.3%  
Price / Book Value ratio x0.31.6 19.3%  
Dividend payout %00-   
Avg Mkt Cap Rs m4,8591,586,770 0.3%   
No. of employees `000NA35.0 0.0%   
Total wages/salary Rs m1,5470-   
Avg. sales/employee Rs Th026,910.4-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th0730.7-  
INCOME DATA
Net Sales Rs m20,598941,863 2.2%  
Other income Rs m4190-   
Total revenues Rs m21,017941,863 2.2%   
Gross profit Rs m2,938243,719 1.2%  
Depreciation Rs m642176,354 0.4%   
Interest Rs m1,74745,300 3.9%   
Profit before tax Rs m96822,065 4.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-138-3,510 3.9%   
Profit after tax Rs m1,10725,575 4.3%  
Gross profit margin %14.325.9 55.1%  
Effective tax rate %-14.3-15.9 89.8%   
Net profit margin %5.42.7 197.9%  
BALANCE SHEET DATA
Current assets Rs m18,877525,936 3.6%   
Current liabilities Rs m11,896383,465 3.1%   
Net working cap to sales %33.915.1 224.0%  
Current ratio x1.61.4 115.7%  
Inventory Days Days7884 93.5%  
Debtors Days Days19893 212.0%  
Net fixed assets Rs m14,269182,706 7.8%   
Share capital Rs m341501 67.9%   
"Free" reserves Rs m15,7980-   
Net worth Rs m16,1391,018,924 1.6%   
Long term debt Rs m4,7061,099,746 0.4%   
Total assets Rs m33,1462,733,150 1.2%  
Interest coverage x1.61.5 104.5%   
Debt to equity ratio x0.31.1 27.0%  
Sales to assets ratio x0.60.3 180.3%   
Return on assets %8.62.6 332.0%  
Return on equity %6.92.5 273.2%  
Return on capital %13.03.2 409.7%  
Exports to sales %21.40-   
Imports to sales %15.20-   
Net fx Rs m1,2190-   
CASH FLOW
From Operations Rs m2,437195,719 1.2%  
From Investments Rs m-6,265-101,165 6.2%  
From Financial Activity Rs m2,490-91,177 -2.7%  
Net Cashflow Rs m241,621 1.5%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 83.58 Rs / USD

Compare PLETHICO PHARMA With: ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare PLETHICO PHARMA With: CHEMO PHARMA  AAYUSH FOOD & HERBS   SUPRIYA LIFESCIENCE   BAFNA PHARMA  FABINO LIFE   



Today's Market

Sensex Today Rallies 599 Points | Private Banks Rally | 4 Reasons Why Indian Share Market is Rising Sensex Today Rallies 599 Points | Private Banks Rally | 4 Reasons Why Indian Share Market is Rising(Closing)

After opening the day deep in red, Indian share markets reversed the trend as the session progressed and ended on firm footing.